The acting CDC director blocked the publication of CDC vaccine research showing COVID-19 vaccine benefits on April 10, citing methodology concerns that expertsThe acting CDC director blocked the publication of CDC vaccine research showing COVID-19 vaccine benefits on April 10, citing methodology concerns that experts

CDC Vaccine Research Showing COVID-19 Benefits Blocked From Publication, Scientists Push Back

2026/04/11 08:30
3 min. skaitymo
Jei turite atsiliepimų ar abejonių dėl šio turinio, susisiekite su mumis crypto.news@mexc.com

The acting CDC director blocked the publication of CDC vaccine research showing COVID-19 vaccine benefits on April 10, citing methodology concerns that experts say reflect a research design used in vaccine effectiveness studies for decades.

Summary
  • The acting CDC director blocked a research paper demonstrating COVID-19 vaccine benefits from being published.
  • Experts say the study’s methodology is a long-established standard for measuring vaccine effectiveness.
  • The move has drawn immediate backlash from the scientific and medical communities as the latest instance of administration interference with public health data.

A decision by the acting director of the Centers for Disease Control and Prevention to block a vaccine effectiveness study from publication has drawn sharp condemnation from researchers and public health experts on April 10. The intervention is being characterized as part of a broader pattern of the administration interfering with the release of government-funded scientific findings.

What Was Blocked and Why It Matters

According to Democracy Now!, the acting CDC director blocked a study demonstrating the benefits of COVID-19 vaccines from publication, citing concerns about the research methodology. Experts responded immediately, noting the design used in the blocked study is the same approach that has been standard practice in vaccine research for decades.

Blocking the study removes from public record data developed using federal resources. Public health researchers described the intervention as highly irregular, noting that methodological disputes are normally addressed through peer review, not by preventing publication entirely.

The Scientific and Medical Backlash

Multiple researchers and public health officials said publicly on April 10 that suppressing vaccine effectiveness data poses direct risks to the clinical and policy decisions that rely on CDC-published evidence. Vaccine protocols at hospitals, clinics, and public health agencies are calibrated against published CDC data, and blocking a study denies practitioners access to evidence they would otherwise use.

The decision has drawn comparisons to other recent cases of the administration restricting data-related activities for political reasons. Anthropic sued the US government in March after alleging retaliation for refusing certain military uses of its technology, with the company arguing the government was using legal mechanisms to restrict information and capabilities that conflicted with its preferences.

A Pattern of Data Interference

Critics say the CDC decision is not an isolated event but part of a consistent approach by the administration to control what scientific information enters the public domain. The acting director offered no alternative process by which the blocked findings could be reviewed and eventually published.

As crypto.news reported, the administration has simultaneously been accelerating the deployment of AI tools across federal agencies, raising questions among civil liberties advocates about who decides what information government agencies produce, share, and suppress.

Atsakomybės apribojimas: Šiame puslapyje publikuojami straipsniai yra paimti iš viešų šaltinių ir pateikiami tik informaciniais tikslais. Jie nebūtinai atspindi MEXC požiūrį. Visos teisės priklauso originaliems autoriams. Jei manote, kad koks nors turinys pažeidžia trečiųjų šalių teises, susisiekite su mumis el. paštu crypto.news@mexc.com, kad jis būtų pašalintas. MEXC negarantuoja pateikiamos informacijos tikslumo, išsamumo ar aktualumo ir neatsako už jokių veiksmų pasekmes, atliktas remiantis šia informacija. Turinys nėra laikomas finansine, teisine ar kita profesionalia konsultacija ir neturėtų būti vertinamas kaip MEXC rekomendacija ar patvirtinimas.

Starter Gold Rush: Win $2,500!

Starter Gold Rush: Win $2,500!Starter Gold Rush: Win $2,500!

Start your first trade & capture every Alpha move